logo-loader
RNS
viewVerona Pharma

PDMR Dealing

PDMR Dealing

LONDON, March 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 22, 2019, Mr. Piers Morgan, CFO of the Company, purchased 20,132 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 64 pence per Ordinary Share and a total purchase price of £12,884.48  Following the acquisition, Mr. Morgan will have an interest in the Company of 113,207 Ordinary Shares, representing 0.11% of the Company’s issued share capital.

The purchase by Mr. Morgan brings the total purchases made by him this month to £32,884.46 and follows the purchases made by the Company’s Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1Details of the person discharging managerial responsibilities/person closely associated

a)


Name


Piers Morgan

2
Reason for the notification

a)

Position/statusChief Financial Officer

b)

Initial notification/AmendmentInitial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

NameVerona Pharma plc

b)

LEI
213800EVI6O6J3TIAL06


4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 5 pence each

GB00BYW2KH80

b)


Nature of the transaction

Piers Morgan purchased 20,132 Ordinary Shares

c)

Price(s) and volume(s)


Price(s)Volume(s)
64 pence per Ordinary Share20,132 Ordinary Shares

d)

Aggregated information

-  Aggregated volume

-  Price

N/A

e)

Date of the transaction22 March 2019

f)

Place of the transactionLondon Stock Exchange, AIM


For further information, please contact:

Verona Pharma plcTel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
[email protected]
  
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison 

Quick facts: Verona Pharma

Price: 48

Market: AIM
Market Cap: £50.56 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE